News
Company’s New Groundbreaking Preclinical Data in NSCLC Models Provides Further Validation for SIL204's Innovative Delivery ...
Silexion is also advancing its next-generation siRNA candidate, SIL204, designed to target a broader range of KRAS mutations and showing significant potential in preclinical studies.
Silexion is also advancing its next-generation siRNA candidate, SIL204, designed to target a broader range of KRAS mutations and showing significant potential in preclinical studies.
GRAND CAYMAN, Cayman Islands, May 29, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA ...
Hosted on MSN1mon
Silexion reports breakthrough in KRAS cancer therapy - MSNIn addition to these structural changes, Silexion Therapeutics Corp has made significant progress in its preclinical studies for SIL-204, a siRNA candidate aimed at treating KRAS-driven cancers.
Silexion is also advancing its next-generation siRNA candidate, SIL204, designed to target a broader range of KRAS mutations and showing significant potential in preclinical studies.
Ilan Hadar, Chairman and CEO of Silexion, commented: “2024 was a transformative year for Silexion, marked by our Nasdaq listing and the advancement of our clinical and preclinical pipeline. Over ...
Hosted on MSN5mon
Silexion Stock Hits Record Intraday Low After Pricing $5M ... - MSNSilexion said it plans to initiate toxicology studies for SIL-204 within the next few months, with phase 2/3 clinical trials scheduled for the first half of 2026. Financially, ...
Cayman Islands, January 15, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for ...
Silexion cautions you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information currently available as of the date a forward-looking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results